



Prior Authorization Request

RINVOQ (upadacitinib)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date



Prior Authorization Request

RINVOQ (upadacitinib)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

RINVOQ (upadacitinib) <input type="checkbox"/> New request <input type="checkbox"/> Renewal request*			
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administration:			
<input type="checkbox"/> Home	<input type="checkbox"/> Physician's office/Infusion clinic	<input type="checkbox"/> Hospital (outpatient)	<input type="checkbox"/> Hospital (inpatient)

* Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:

Rheumatoid Arthritis

- For the treatment of moderately to severely active rheumatoid arthritis in an adult, AND
- The patient has had an inadequate response to a minimum 12-week trial of methotrexate in combination with another disease modifying anti-rheumatic drug (DMARD) *(Please list prior therapies in the chart below)*, OR
- Where combinations of non-biologic DMARDs are impossible, the patient has tried 3 consecutive non-biologic DMARDs, unless patient has a documented intolerance to DMARDs *(Please list prior therapies in the chart below)*

Psoriatic Arthritis

- For the treatment of active psoriatic arthritis in an adult, AND
- The patient has had an inadequate response or has a documented intolerance to at least 2 disease modifying anti-rheumatic drugs (DMARDs), or to another biologic response modifier *(Please list prior therapies in the chart below)*

Ankylosing Spondylitis

- For the treatment of ankylosing spondylitis in an adult, AND
- The patient has a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 4 or greater on a 10-point scale, AND
- The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) for a minimum of 2 weeks each *(Please list prior therapies in the chart below)*, AND
- The patient has had an inadequate response or has a documented intolerance to a biologic response modifier *(Please list prior therapies in the chart below)*



Prior Authorization Request

RINVOQ (upadacitinib)

Atopic Dermatitis

INITIAL

- For the treatment of moderate-to-severe atopic dermatitis (AD), AND
- The patient is 12 years of age or older, AND
- The patient has an affected body surface area (BSA) of 10% or greater, or there is involvement of the patient's face, hands, feet or genital region, AND
- The patient has an Investigator's Global Assessment (IGA) score of 3 or greater, AND
- The patient has an Eczema Area and Severity Index (EASI) score of 16 or greater, AND
- The patient has had an inadequate response or has a documented intolerance to at least 2 topical agents that are high potency corticosteroids or calcineurin inhibitors (*Please list prior therapies in the chart below*), AND
- The patient has had an inadequate response or has a documented intolerance to a systemic treatment, if an adult (*Please list prior therapies in the chart below*)

RENEWAL

- The patient has demonstrated improvement defined as 75% or greater improvement from baseline in EASI score. Please indicate patient's baseline and current EASI score below:

BASELINE		CURRENT	
Date (YYYY-MM-DD)	EASI score	Date (YYYY-MM-DD)	EASI score

Non-Radiographic Axial Spondyloarthritis

- For the treatment of non-radiographic axial spondyloarthritis in an adult, AND
- The patient has objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), AND
- The patient has had an inadequate response or has a documented intolerance to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) for a minimum of 2 weeks each (*Please list prior therapies in the chart below*), AND
- The patient has had an inadequate response or has a documented intolerance to a biologic disease modifying anti-rheumatic drug (DMARD) (*Please list prior therapies in the chart below*)

Ulcerative Colitis

- For the treatment of moderately to severely active ulcerative colitis in an adult, AND
- The patient has had an inadequate response or has a documented intolerance to corticosteroids and to either aminosalicylates or immunomodulators (*Please list prior therapies in the chart below*), AND
- The patient has tried and failed a biologic response modifier (*Please list prior therapies in the chart below*)



Prior Authorization Request

RINVOQ (upadacitinib)

Crohn's Disease

- For the treatment of moderately to severely active Crohn's disease in an adult, AND
- The patient has had an inadequate response or has a documented intolerance to either aminosalicylates, immunomodulators, or corticosteroids (*Please list prior therapies in the chart below*), AND
- The patient has tried and failed a biologic response modifier (*Please list prior therapies in the chart below*)

Giant Cell Arteritis

- For the treatment of giant cell arteritis (GCA) in an adult, AND
- RINVOQ will be used in combination with a tapering dose of corticosteroids

OR

- None of the above criteria applies.

Relevant additional information:

2. Please list previously tried therapies

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>



Prior Authorization Request

RINVOQ (upadacitinib)

SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services
1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services
6985 Financial Drive, Suite 300
Mississauga, ON L5N 0G3